IP Library Granted Patent US 7,678,774
Granted Patent B2
US 7,678,774 · App. 11/698,038 · Granted Mar 16, 2010

Treating severe acute respiratory syndrome

Assignee: Hemispherx Biopharma
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,678,774
App. No.
11/698,038
Granted
Mar 16, 2010
Kind
B2
Abstract

Severe acute respiratory syndrome is treated with a natural human alpha interferon, a dsRNA or both natural human alpha interferon and a dsRNA.

Claims (12)

1. A method of treating severe acute respiratory syndrome comprising administering to an infected subject a dsRNA; wherein the dsRNA is rI n .r(C 11-14 ,U) n , Poly A.Poly U, or rI n .r(C 29 ,G) n in which n is an integer and r is ribo.

2. A method of treating severe acute respiratory syndrome comprising the coordinated administration to an infected subject of (1) a natural human alpha interferon and (2) a dsRNA: wherein the dsRNA is rI n .r(C 11-14 ,U) n , Poly A.Poly U, or rI.r(C 29 ,G) n in which n is an integer and r is ribo.

3. The method according to claim 1 , wherein the dsRNA is rI n .r(C 12 U) n .

4. The method according to claim 2 , wherein the dsRNA is rI n .r(C 12 U) n .

5. The method according to claim 2 , wherein the interferon is administered orally.

6. The method according to claim 2 , wherein the interferon is administered intravenously.

7. The method according to claim 2 , wherein the interferon is administered intramuscularly.

8. The method according to claim 2 , wherein the interferon is administered subcutaneously.

9. The method according to claim 4 , wherein the interferon is administered orally.

10. The method according to claim 4 , wherein the interferon is administered intravenously.

11. The method according to claim 4 , wherein the interferon is administered intramuscularly.

12. The method according to claim 4 , wherein the interferon is administered subcutaneously.

Assignments (2)
CHANGE OF NAME Recorded Nov 4, 2019
From: HEMISPHERX BIOPHARMA, INC.
To: AIM IMMUNOTECH INC.
Reel/Frame 050916/0938 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2019
From: CARTER, WILLIAM A.; STRAYER, DAVID
To: HEMISPHERX BIOPHARMA
Reel/Frame 050836/0176 →
Continuity (4)
Division 1084247400 · May 11, 2004
Provisional Application 6047089300 · May 16, 2003
Provisional Application 6051788200 · Nov 7, 2003
Related Publication 20070141080A1 · Jun 21, 2007